[Treatment of ovarian cancer at FIGO stage III and IV--prognostic factors for patients receiving neoadjuvant chemotherapy].
Among 165 patients with stage III and IV ovarian cancer, 74 received neoadjuvant (NA) chemotherapy. The response to NA chemotherapy was 85% (17/20) for CP, 79% (26/33) for CAP, and 33% (7/21) for FAMT. Following NA chemotherapy, 43 patients received debulking surgery, of whom 34 received optimal debulking (OD: residuum < 2cm). The remaining 31 patients did not receive debulking, of whom 18 responded to NA chemotherapy. The rate of OD was significantly higher in patients with CAP/CP than in those with FAMT. There was a tendency for the OD rate to be higher in patients with the serous or endometrioid type than in those with the clear cell or mucinous type. The procedures employed in 34 patients receiving OD following NA chemotherapy included basic surgery for 24 patients and more extensive surgery for 10 patients. Significant prognostic factors for patients receiving NA chemotherapy were, 1) response to NA chemotherapy, 2) radicality of debulking following NA chemotherapy, 3) regimen of NA chemotherapy (CAP/CP), and 4) histologic type (serous, endometrioid).